The type 2 diabetes medication Tradjenta (linagliptin) has been linked to severe and potentially life-threatening side effects including pancreatitis, pancreatic cancer and bullous pemphigoid.
Free Confidential Lawsuit Evaluation: If you or a loved one got pancreatic cancer after taking Tradjenta, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.
Update: Tradjenta May Increase Risk of Rhabdomyolysis
December 1, 2017 - Patients who took Tradjenta and other medicines from the DPP-4 inhibitor class have been diagnosed with a severe muscle disorder called rhabdomyolysis, according to a recent FDA Warning. The agency is determining whether the drugs' risks outweigh their benefits, and will notify the public as the information becomes available.
What’s the problem with Tradjenta?
First approved by the U.S. Food & Drug Administration (FDA) in 2011, Tradjenta is a relatively new addition to a class of type 2 diabetes medications known as incretin mimetics. Drugs from this class are designed to regulate blood sugar levels and manage the symptoms associated with type 2 diabetes mellitus.
Unfortunately, despite demonstrating considerable effectiveness in this capacity, incretin mimetics like Tradjenta have recently become a subject of increasing concern. The active ingredient found in Tradjenta, linagliptin, has been associated with the onset of severe, potentially life-threatening side effects. Of special concern are reports that link Tradjenta to the onset of certain types of cancer. Patients taking the drug may increase their risk of developing pancreatic cancer or thyroid cancer, both of which can be fatal. Therefore, those diagnosed with these diseases after taking Tradjenta may be eligible to participate in the filing of a Tradjenta lawsuit.
Tradjenta Side Effects
Serious side effects associated with incretin mimetic diabetes drugs like Tradjenta have been reported to include:
Pancreatic cancer - Disease that originates in the tissues of the pancreas, an abdominal organ that produces such vital hormones as insulin, glucagon, somatostatin, and pancreatic polypeptide. Pancreatic cancer often has a poor long-term outlook, even when diagnosed in its early stages. The disease typically spreads rapidly and is hard to detect early on, which is a major reason why it’s a leading cause of cancer death among men and women in the United States. Signs and symptoms of Tradjenta-induced pancreatic cancer may include:
- Loss of appetite
- Weight loss
- Jaundice (yellowing of the skin and eyes)
Thyroid cancer - Disease of the thyroid gland, a butterfly-shaped organ located at the base of the neck. Most cases of thyroid cancer can be cured with treatment if they are detected early enough. Tradjenta thyroid cancer symptoms may include:
- Lump in the front of the neck
- Enlargement of the thyroid
- Swelling in the neck
- Pain in the front of the neck that may stretch to the ears
- Change in voice or hoarseness
- Breathing problems (the feeling that you are breathing through a straw)
- Cough that does not go away and is not caused by a cold
- Cough with blood
- Swallowing problems
Incretin Mimetic Drug List
In addition to Tradjenta, other potentially dangerous incretin mimetics that may increase the risk of adverse effects include:
- Byetta (exenatide)
- Bydureon (exenatide)
- Janumet (metformin and sitagliptin)
- Janumet XR (sitagliptin and metformin HCl extended-release) 
- Januvia (sitagliptin)
- Jentadueto (linagliptin and metformin)
- Kazano (alogliptin and metformin)
- Kombiglyze XR (saxagliptin and metformin)
- Nesina (alogliptin)
- Onglyza (saxagliptin)
- Oseni (alogliptin and pioglitazone)
- Victoza (liraglutide)
Tradjenta and Bullous Pemphigoid
A study published in the journal Dermatology  in 2016 looked at 3 cases of DPP-4 inhibitor use associated with bullous pemphigoid, a rare skin disorder that causes symptoms of blistering on the arms, legs, abdomen, and mucous membranes. All 3 patients showed a clear temporal relationship between DPP-4 inhibitor therapy and the onset of BP. One case was due to Tradjenta use, while the other 2 cases were linked to a combination of vildagliptin-metformin.
DPP-4 Inhibitors Linked to Severe Joint Pain
August 28, 2015 - The FDA warned  today that Tradjenta and other DPP-4 inhibitor diabetes medications may cause joint pain that can be severe and disabling. The agency stated that it has added a new warning about the risk to the labels of all products in the DPP-4 inhibitor class.
Do I have a Tradjenta Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Tradjenta lawsuits. We are handling individual litigation nationwide and currently accepting new cases in all 50 states.
Free Confidential Case Evaluation: Again, if you were diagnosed with pancreatic cancer after taking Tradjenta, you should contact our law firm immediately. You may be entitled to compensation by filing a class action suit and our lawyers can help.